Bottom line: WuXi PharmaTech’s privatization will be followed by at least 3-4 more similar buy-outs this year for US-traded Chinese stocks, including a 50-50 chance that Renren will attempt a privatization by mid-year.
Wuxi Pharma gets buy-out bid
I’m beginning to feel like I should start a betting list of Chinese candidates that may de-list from New York, following word that unappreciated drug maker WuXi PharmaTech (NYSE: WX) has become the latest company to announce a management-led buy-out. At the same time, dying social networking (SNS) site Renren(NYSE: RENN) has also announced results of its own recent Dutch auction-style share buyback plan, which also hints that it could become the next company to attempt a privatization. Read Full Post…
Bottom line: Focus Media’s plan for a backdoor listing in China stands a better than 50 percent chance of success, potentially opening a new re-listing path for Chinese firms whose shares are undervalued in New York.
Focus Media eyes China backdoor listing
Former advertising services high-flyer Focus Media is eying a plan to become listed again, with an ambitious target of tripling its value from just 2 years ago when it privatized. If the plan really works, it could create an attractive template for a return to publicly-traded status for the group of about a dozen Chinese companies that were formerly listed in New York but privatized after their shares became undervalued. The key to the plan appears to be a decision to list back at home in China, where Focus’ name is more familiar and local investors are far less sophisticated and prone to hype and overinflating values of well-known companies. Read Full Post…
Technology giant Legend Holdings has grabbed headlines in recent days with news of a record investment by its private equity arm in a leading British pizza chain, its first major overseas foray. The deal saw Legend’s Hony Capital agree to pay $1.6 billion for the PizzaExpress chain, as part of a growing trend by Chinese firms to invest in the overseas food and retail sectors.
The purchase comes as Legend gears up for an IPO as early as later this year, offering investors a chance to buy into a diversified group whose biggest asset is its controlling stake in PC giant Lenovo (HKEx: 992). But the bigger headline in the Legend story is reports that the company is strongly considering staging its listing in Hong Kong rather than its native China. Read Full Post…
I’ll start this post with a major disclaimer, since one of my main reasons is simple sentimentality for writing about the newly announced buyout of New York-listed hospital operator Chindex (Nasdaq: CHDX) by a unit of the aggressive Fosun Group. When I first arrived in Beijing in 1987 as recent college graduate, I worked briefly in Chindex’s Beijing offices, which at the time were in the old Xiyuan hotel near the Beijing zoo. Since then, the company has transformed from its early days as an importer of medical and industrial equipment to its current focus on building and operating hospitals and clinics. Along the way it also made an IPO, and has quietly grown into a company with a market value of nearly $300 million. Read Full Post…
It seems appropriate that 2 more longtime-listed Chinese companies are bowing out of New York as we head into the final days of 2013, with word that shareholders have approved plans to privatize telecoms software maker AsiaInfo-Linkage (Nasdaq: ASIA) and drugmaker Simcere Pharmaceutical (NYSE: SCR). AsiaInfo was the more lively of these 2 de-listing stories, with a narrow majority of shareholders approving a buy-out offer after several months of protest from others who thought the price was too low. Meantime, Simcere’s looming privatization raises the question of what’s next for this neglected company, whose foreign partners include Bristol-Myers Squbb (NYSE: BMY) and Merck (NYSE: MRK). Read Full Post…
Firms threaten lawsuits over Giant Interactive buyout
It may be quiet in the US during the Thanksgiving holiday, but shareholder lawyers were hard at work scrutinizing the new management-led buyout offer for online game operator Giant Interactive (NYSE: GA), with at least 2 hinting they will file lawsuits to seek a better bid. This is the second time we’ve seen lawyers question a buyout offer for a US-listed Chinese firm, following a similar development for privatizing telecoms software maker AsiaInfo-Linkage (Nasdaq: ASIA). Both cases highlight the challenges that such buy-outs can face, especially when buyer groups have strong ties to the companies they are seeking to privatize. Read Full Post…
The following press releases and media reports about Chinese companies were carried on August 29. To view a full article or story, click on the link next to the headline.
══════════════════════════════════════════════════════
Chinese Shoppers Set To Become World Leaders Online (English article)
Suntech (NYSE: STP) Announces Director Resignations and Election of New Chairman (PRNewswire)
US-listed drug maker Simcere Pharmaceutical (NYSE: SCR) must be eagerly looking forward to completing its pending privatization, following the release of its latest quarterly results that show the fast-growing Chinese healthcare market is suddenly losing some of its luster. Simcere is just the latest drug maker to encounter headwinds in China, where fierce competition and strict government oversight are suddenly giving both domestic and foreign drug makers a major headache. Many of those companies were hoping to make big bucks as China rolled out a new national healthcare network to replace its old system where everyone got medical care through their state-run work units. But Beijing is pushing back by showing it aims to get maximum value for its money, and also that it won’t tolerate aggressive sales tactics practiced by many companies. Read Full Post…
The following press releases and media reports about Chinese companies were carried on August 14. To view a full article or story, click on the link next to the headline.
══════════════════════════════════════════════════════
Baidu (Nasdaq: BIDU) In Talks To Acquire Nuomi, Ding Ding Map (English article)
UPS (NYSE: UPS) Expands Logistics Reach To Meet Emerging Demand in China (Businesswire)
The following press releases and media reports about Chinese companies were carried on June 25. To view a full article or story, click on the link next to the headline.
══════════════════════════════════════════════════════
China Cash Squeeze Eases, But Bank Shares Take Big Hit (English article)
A few interesting news bits on the medical front are spotlighting both the opportunities and risks that drug and medical equipment makers face in developing the China market. On the opportunity side, Bristol-Myers Squibb (NYSE: BMY) has announced an expansion of its relationship with Simcere Pharmaceutical (NYSE: SCR) to introduce its drugs into China. Meantime, homegrown medical equipment maker Mindray Medical (NYSE: MR) is also banking on the market’s potential with its newly announced acquisition of a US ultrasound equipment maker. But US drug giant Johnson & Johnson (NYSE: JNJ) is also finding the market contains some risks, as it comes under fire for double standards related to its product recall policies in China. Read Full Post…
